Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valiant LaboratoriesNSE:VALIANTLAB -0.55%52 Debt-to-EBITDA is 2.32 as of Mar. 2026, which is 32% below its 10-year median of 3.41. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 52/100 and a GF Value™ of ₹102.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Valiant Laboratories ranks worse than 81.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Valiant Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:VALIANTLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 3.41 Max: 161.11
Current: 5.3
During the past 6 years, the highest Debt-to-EBITDA Ratio of Valiant Laboratories was 161.11. The lowest was 0.01. And the median was 3.41.
NSE:VALIANTLAB's Debt-to-EBITDA is ranked worse than 81.74% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs NSE:VALIANTLAB: 5.30
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Valiant Laboratories Debt-to-EBITDA Related Terms
Valiant Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Valiant Laboratories (NSE:VALIANTLAB) has a Debt-to-EBITDA of 2.32 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Valiant Laboratories. This is 32% below median its historical median of 3.41. Over the past decade, Valiant Laboratories' Debt-to-EBITDA has ranged from 0.01 to 161.11. According to the industry distribution chart, Valiant Laboratories ranks #564 out of 690 companies in the Drug Manufacturers industry, placing it in the top 81.7%.
Is Valiant Laboratories' Debt-to-EBITDA too high?
Valiant Laboratories' current Debt-to-EBITDA of 2.32 is 32% below median its 10-year median of 3.41. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 161.11. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Valiant Laboratories' value of 2.32 is 38.9% above this industry median. Based on the distribution chart, Valiant Laboratories ranks #564 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #564 out of 690 companies for Debt-to-EBITDA. This places Valiant Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Valiant Laboratories' value of 2.32 is 38.9% above this benchmark. Historically, Valiant Laboratories' own Debt-to-EBITDA has ranged from 0.01 to 161.11 over the past decade. While the company's 10-year median is 3.41 vs. the industry median of 1.67, Valiant Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Debt-to-EBITDA of 2.32 is 38.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Valiant Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Debt-to-EBITDA is 2.32, which is 32% below median its own 10-year median of 3.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.15, compared to a current price of ₹63.40 — trading 37.9% below its estimated fair value. The current Debt-to-EBITDA is 2.32, which is 32% below median its 10-year median of 3.41 and 38.9% above the Drug Manufacturers industry median of 1.67. Valiant Laboratories' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Debt-to-EBITDA is 2.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹63.40 is trading 37.9% below its estimated GF Value™ of ₹102.15.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Debt-to-EBITDA: 2.32 (32% below median its 10-year median of 3.41)
GF Value™: ₹102.15 vs. price of ₹63.40 (37.9% below fair value)
Industry Position: 38.9% above the Drug Manufacturers median (#564 of 690)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
52GF Score
Get the complete analysis for NSE:VALIANTLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
